Reference : Development of new drugs for an old target — the penicillin binding proteins.
Scientific journals : Article
Life sciences : Biochemistry, biophysics & molecular biology
Life sciences : Microbiology
Human health sciences : Immunology & infectious disease
http://hdl.handle.net/2268/134239
Development of new drugs for an old target — the penicillin binding proteins.
English
Zervosen, Astrid mailto [Université de Liège - ULg > > Centre de recherches du cyclotron >]
Sauvage, Eric mailto [Université de Liège - ULg > > Centre d'ingénierie des protéines >]
Frère, Jean-Marie mailto [Université de Liège - ULg > > Centre d'ingénierie des protéines >]
Charlier, Paulette mailto [Université de Liège - ULg > Département des sciences de la vie > Cristallographie des macromolécules biologiques >]
Luxen, André mailto [Université de Liège - ULg > Département de chimie (sciences) > Chimie organique de synthèse >]
2012
Molecules
17
11
12478-505
Yes (verified by ORBi)
International
1420-3049
Switzerland
[en] non-beta-lactam ; Penicillin Binding Protein
[en] The widespread use of β-lactam antibiotics has led to the worldwide appearance of drug-resistant strains. Bacteria have developed resistance to β-lactams by two main mechanisms: the production of β-lactamases, sometimes accompanied by a decrease of outer membrane permeability, and the production of low-affinity, drug resistant Penicillin Binding Proteins (PBPs). PBPs remain attractive targets for developing new antibiotic agents because they catalyse the last steps of the biosynthesis of peptidoglycan, which is unique to bacteria, and lies outside the cytoplasmic membrane. Here we summarize the “current state of the art” of non-β-lactam inhibitors of PBPs, which have being developed in an attempt to counter the emergence of β-lactam resistance. These molecules are not susceptible to hydrolysis by β-lactamases and thus present a real alternative to β-lactams. We present transition state analogs such as boronic acids, which can covalently bind to the active serine residue in the catalytic site. Molecules containing ring structures different from the β-lactam-ring like lactivicin are able to acylate the active serine residue. High throughput screening methods, in combination with virtual screening methods and structure based design, have allowed the development of new molecules. Some of these novel inhibitors are active against major pathogens, including methicillin-resistant Staphylococcus aureus (MRSA) and thus open avenues new for the discovery of novel antibiotics.
Centre de Recherches du Cyclotron - CRC ; Centre d'Ingénierie des Protéines - CIP
Professionals ; Students ; Others
http://hdl.handle.net/2268/134239

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
molecules-17-12478.pdfPublisher postprint450.05 kBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.